Should the patent system for new medicines be abolished?

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 5, 2007, Pages 488-490

  DiMasi, J A ^a   Grabowski, H G ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; PATENT; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT SURVEY; UNITED STATES; WELFARE;

BIOMEDICAL RESEARCH; COMMERCE; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; FINANCING, GOVERNMENT; HUMANS; INSURANCE COVERAGE; LEGISLATION, DRUG; ORPHAN DRUG PRODUCTION; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; PUBLIC POLICY; UNITED STATES;

EID: 35448937289     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100393     Document Type: Short Survey

References (19)

1. Levy, R. & Wickelgren, A. Competition policy issues for regulators: a U.S. perspective on pharmaceutical industry cases before the Federal Trade Commission. In Consolidation and Competition in the Pharmaceutical Industry (ed. Kettler, H.) 106-117 (Office of Health Economics, London, UK, 2001).
2. Nordhaus, W. The health of nations: the contribution of improved health to living standards. In Measuring the Gains from Medical Research: An Economic Approach (eds. Murphy, K.M. & Topel, R.) 9-40 (Chicago University Press, Chicago, 2003).
3. Becker, G., Philipson, T. & Soares, R. The quantity and quality of life and the evolution of world inequality. Amer. Econ. Rev. 95, 277-291 (2005).
4. DiMasi, J.A., Hansen, R.W. & Grabowski, H. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185 (2003).
5. Lakdawalla, D.N. & Sood, N. Health Insurance as a Two-Part Pricing Contract 〈http://works.bepress.com/darius_lakdawalla/29〉 (2006). Accessed 20 August 2007.
6. The Free Market Drug Act of 2004. H.R. 5155, 108th Congress (2004).
7. Medical Innovation Prize Act of 2005. H.R. 417, 109th Congress (2005).
8. Medical Research and Development Treaty (MRDT) 〈http://www.cptech. org/workingdrafts/rndtreaty4.pdf〉 (2005). Accessed 20 August 2007.
9. Love, J. Measures to enhance access to medical technologies, and new methods of stimulating medical R&D. U.C. Davis Law Rev. 40, 679-715 (2007).
10. DiMasi, J.A. & Grabowski, H.G. Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&D 〈http://www.who.int/intellectualproperty/news/en/Submission3. pdf〉 (2004). Accessed 20 August 2007.
11. Farlow, A. A Global Medical Research and Development Treaty: An Answer to Global Health Needs? (International Policy Network, London, UK, 2007).
12. Tirole, J. The Theory of Industrial Organization. (MIT Press, Cambridge, MA, 1988).
13. Ridley, D.B., Grabowski, H.G. & Moe, J. Developing drugs for developing countries. Health Aff. 25, 313-324 (2006).
14. Nwaka, S. & Ridley, R.G. Virtual drug discovery and development for neglected diseases through public-private partnerships. Nat. Rev. Drug Discov. 2, 919-928 (2003).
15. Ridley, R.G. Product development publicprivate partnerships for diseases of poverty: are there more efficient alternatives? are there limitations? Prepared for the Initiative on Public-Private Partnerships Workshop. Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential role of Public-Private Partnerships (London, 15-16 April 2004).
16. Kremer, M. Pharmaceuticals and the developing world. J. Econ. Persp. 16, 67-90 (2002).
17. Berndt, E.R. et al. Advanced Purchase Commitments for a Malaria Vaccine: Estimating Costs and Effectiveness. National Bureau of Economic Research, NBER Working Paper No. 11288 (2005).
18. GAVI Alliance. Five Nations and the Bill and Melinda Gates Foundation Launch Advanced Market Commitments for Vaccines to Combat Deadly Disease in Poor Nations 〈http://www.vaccineamc.org/media/launch_event_01.html〉 (2007). Accessed 20 August 2007.
19. Grabowski, H. Increasing R&D incentives for neglected diseases: lessons from the Orphan Drug Act. In International Public Goods, and Transfer of Technology under a Globalized Intellectual Property Regime (eds. Maskus, K.I. & Reichman, J.H.) 457-480 (Cambridge University Press, Cambridge, UK, 2005).